Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.

Trial Details

NCT ID
NCT05256641
Phase
PHASE1 / PHASE2
Sponsor
Jonsson Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Acalabrutinib
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sacramento, California, United States|38.58157,-121.4944
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Ages 18-70 years
  • One of the following:
  • Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) …
  • High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →